请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-NDG B2m KO mice plus
Strain Name 

B-NDG-B2mtm1 Fcrntm1(mB2m)Bcgen/Bcgen

Common Name 

B-NDG B2m KO mice plus

Background B-NDG Catalog number  110601
Related Genes 

B2m (beta-2 microglobulin) ;
Fcgrt (Fc receptor, IgG, alpha chain transporter,as known as Fcrn)

NCBI Gene ID
12010,14132

Mice Description



Human PBMC-engrafted humanized mice are attractive models for in vivo analysis of human immune responses. We previously reported that human PBMCs could be engrafted in B-NDG mice successfully. However, because of severe xenogeneic graft versus host disease (xeno-GVHD) in these mice, there is a limited window for experiments. The onset of GvHD is directly related to the degree of engraftment of human T cells. The mismatches between human and mouse MHCs are the main cause of GvHD after human PBMC transplantation1. Data have shown that knockout of MHC class I and/or II molecules in mice attenuates GvHD and prolongs the window period for experiments after human PBMC transplantation.

MHC class I molecules consist of two subunits, α and β chains. The B2m (beta-2-microglobulin) gene encodes the β chain. Knockout of the B2m gene in mice can result in the inability to form intact MHC class I molecules and cannot be expressed on the cell surface to exert antigen presentation, thereby alleviating GvHD. However, B2M is also a subunit of FcRn, the Fc receptor for IgG. The structure of FcRn is similar to that of MHC class I molecules, consisting of the α chain encoded by the Fcgrt gene and the β chain encoded by the B2m gene. FcRn can bind to antibodies and prolong the half-life of antibodies. Loss of B2M expression results in a shortened half-life of the antibody in mice.

Biocytogen developed the B-NDG B2m KO plus mice, which knocked out the mouse B2m gene, while the mouse B2m and Fcrgt fusion gene were knocked in at the mouse Fcgrt gene locus. This mouse has a background of B-NDG mice and does not express MHC class I molecules on the cell surface. Compared with B-NDG mice, this mouse has no difference in the metabolism of IgG and is effective in delaying the development of GvHD. This model can be used to investigate the in vivo mechanism of xenogeneic graft versus host disease (GvHD) and to evaluate the efficacy of antitumor drugs using humanized mice reconstituted with human PBMCs.



Expression analysis of MHC class l molecules



from clipboard



Expression of MHC class I in B-NDG B2m KO plus mice

Blood cells, splenocytes, bone marrow cells were respectively collected from B-NDG B2m KO plus mice, B-NDG mice, NOD scid mice (n=5). Expression of MHC class I (H-2Kb) was analyzed with FACS. Results showed that MHC class I molecule was detectable in B-NDG mice and NOD scid mice. But there was no MHC class I molecule detectable in B-NDG B2m KO plus mice.



Expression analysis of MHC class II molecules



from clipboard


Expression of MHC class II in B-NDG B2m KO plus mice

Blood cells, splenocytes, bone marrow cells were respectively collected from B-NDG B2m KO plus mice, B-NDG mice, NOD scid mice (n=3). Expression of MHC class II (I-AK) was analyzed with FACS. Results showed that the MHC class II molecules were all detectable in dendritic cells and macrophages of the three strains of mice.



Flow cytometric analysis of T , B and NK cells


from clipboard


Blood cells, splenocyte, cells were collected from B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice (n=5) and analyzed by flow cytometry with T, B and NK cells. T, B and NK cells were not detectable in B-NDG B2m KO  plus and B-NDG mice. T, B cells were undetectable and NK cells were detectable in NOD scid mice. T, B and NK cells were detectable in C57BL/6 mice.


Flow cytometric analysis of Macrophages


from clipboard


Blood cells, splenocyte, Bone marrow cells were collected from B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice (n=5) and analyzed by flow cytometry with Macrophages(mCD45+mCD11b+mF4-80+). Macrophages were detectable in B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice.


Flow cytometric analysis of DC cells and monocytes


from clipboard


Blood cells, splenocyte, Bone marrow cells were collected from B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice (n=5) and analyzed by flow cytometry with DC cells (mCD45+mCD11b+mCD11c) and monocytes (mCD45+mCD11b+mLy6c). DC cells and monocytes were detectable in B-NDG B2m KO  plus, B-NDG, NOD-scid and C57BL/6 mice.


Histopathological sections of tissues from B-NDG B2m KO mice plus and control mice



Histopathological sections of tissues from B-NDG B2m KO mice plus and control mice.

(A) Spleen from C57BL/6 has normal structure with well-defined follicles. (B) Spleen from NOD-scid show hypoplasia of  white pulp. (C, D) Spleen from both B-NDG and B-NDG B2m KO mice plus show complete loss of follicular structure. (E) Thymic lobes from C57BL/6 have normal structure with a well-defined cortex. (F) Thymic lobes from NOD-scid mice are hypoplastic and lack a defined cortex.(g) Thymic lobes from B-NDG mice are severely hypoplastic and lack a defined cortex. (H) B-NDG B2m KO mice plus show no thymic lobes on the normal anatomy location.


PK analysis of human IgG in serum



from clipboard


The PK of human IgG in B-NDG B2m KO mice plus was similar to that in wild-type mice.

B-NDG, B-NDG B2m KO mice, B-NDG B2m KO mice plus and C57BL/6 mice were treated with human IgG (n=5). Blood samples were collected at different time point for the PK assay. Results showed that the PK of B-NDG mice and B-NDG B2m KO mice plus groups were basically in line with the pharmacokinetic characteristics, with no difference compared with wild-type C57BL/6 mice, and the drug concentration of B-NDG B2m KO mice group could not be measured at the time point 2 days later.



Effectively delayed the onset of GvHD induced by human PBMC engraftment



from clipboard 


B-NDG B2m KO mice plus can effectively delay the onset and reduce the severity of GvHD induced by human PBMC engraftment.

B-NDG B2m KO plus mice (n = 5, female, 11-week-old) and B-NDG mice (n = 6, female, 10-week-old) were injected intravenously with human PBMCs (2E7) from three healthy donors on day 0, and each mouse was scored twice weekly for clinical signs according to GvHD scoring criteria. The results showed that B-NDG B2m KO plus mice could significantly prolong the survival time, delay the occurrence and reduce the severity of GvHD compared with B-NDG mice in the GvHD model constructed after human PBMC transplantation.



B-NDG B2m KO mice plus are well suited for human immune system engraftment




B-NDG B2m KO mice plus are well suited for human immune system engraftment.

Human PBMC (5E6) were intravenous implanted into homozygote B-NDG B2m KO mice plus and  B-NDG mice (female, 7-week-old, n=6). Representative flow cytometric analysis of PBMCs from mice after engraftment with human PBMC.B-NDG B2m KO mice plus show a little change in body weight and exhibit longer survival compared with B-NDG. The result showed that human PBMC engrafted humanized mice model was successfully constructed.


Anti-tumor efficacy in PBMC RKO model in B-NDG B2m KO mice plus


from clipboard


Antitumor activity of the combination of pembrolizumab (anti PD-1) and ipilimumab (anti CTLA4) in B-NDG B2m KO mice plus reconstituted with hPBMCs.

Human colon cancer RKO cells (5E6) were subcutaneously implanted after human PBMCs (1E7) injected into B-NDG B2m KO mice plus (n=7/8). Mice were grouped when tumor volume reached approximately 100-150 mm3. Anti-human PD-1 antibody and anti-human CTLA4 antibody (in house) were injected intraperitoneally. The results showed that combination of anti-hPD-1 antibody and anti-CTLA4 antibody can effectively inhibited the tumor growth, indicating that B-NDG B2m mice plus reconstituted with PBMCs provides a powerful preclinical model for in vivo evaluation of antibodies. Values are expressed as mean ± SEM.




In vivo efficacy of CAR-T can be effectively evaluated in B-NDG B2m KO mice plus


from clipboard


A human lung cancer model was established by implanting NCI-H226 into B-NDG B2m KO plus mice, which can effectively evaluate the in vivo efficacy of CAR-T therapy.

Human lung cancer cells NCI-H226 (1E7) were implanted into B-NDG B2m KO mice plus. Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with CAR-T cells (5E5) with schedules indicated in panel. (A) Tumor volume. (B) Body weight changes during treatment. The results showed that CAR-T cells differently inhibited tumor growth in B-NDG B2m KO mice plus. Within 5 weeks of CAR-T treatment, the body weight of mice in the treatment groups continued to increase without significant GvHD.



Bispecific antibody in vivo efficacy evaluation in B-NDG B2m mice plus reconstituted with human PBMCs

Figure 12. B-NDG B2m mice plus reconstituted with PBMCs were used for anti PD-1×PD-L1 bispecific antibody efficacy studies 
RKO cells (5E6) were subcutaneously implanted after human PBMCs (5E6) implanted into B-NDG B2m mice plus (female, 9 week-old, n=6). The animals were grouped into control and treatment when the tumor size was approximately 100 mm3. (A) Anti human PD-1×PD-L1 bispecific antibody inhibited RKO tumor growth in human PBMC reconstituted B-NDG B2m mice plus. (B) Body weight changes during treatment. Anti PD-1×PD-L1bispecific antibody shows significant tumor inhibitory effects. The results indicate that B-NDG B2m mice plus reconstituted with PBMCs provides a powerful preclinical model for in vivo evaluation of  antibodies. Values are expressed as mean ± SEM.


Summary

  1. Flow cytometric analysis of MHC class l and Il expression.  MHC class I were not detectable in B-NDG B2m KO mice plus .
  2. Flow cytometric analysis using specific markers for T, B and NK cells. T, B and NK cells were not detectable in B-NDG B2m KO  plus.
  3. Determination of plasma concentrations of human IgG in different mice .The results showed that the PK results of B-NDG and B-NDG B2m KO mice plus groups were basically in line with the pharmacokinetic characteristics, with no difference compared with wild-type mice Physiological function
  4. B-NDG B2m KO mice plus are well suited for human immune system engraftment. Human PBMC (5E6) were intravenous implanted into homozygote B-NDG B2m KO mice plus and B-NDG mice (female, 7-week-old, n=6). Representative flow cytometric analysis of PBMCs from mice after engraftment with human PBMC. B-NDG B2m KO mice plus show a little change in body weight and exhibit longer survival compared with B-NDG.